EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+11.07%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.1B
AUM Growth
-$1.95B
(-64%)
Cap. Flow
-$2.1B
Cap. Flow
% of AUM
-190.3%
Top 10 Holdings %
Top 10 Hldgs %
55.43%
Holding
359
New
34
Increased
188
Reduced
93
Closed
36
Top Buys
| 1 |
STAAR Surgical
STAA
|
$42.6M |
| 2 |
Sea Limited
SE
|
$22.9M |
| 3 |
Mercado Libre
MELI
|
$19.7M |
| 4 |
NIO
NIO
|
$19.6M |
| 5 |
Meta Platforms (Facebook)
META
|
$16.1M |
Top Sells
| 1 |
Alibaba
BABA
|
$1.32B |
| 2 |
JD.com
JD
|
$334M |
| 3 |
Baidu
BIDU
|
$314M |
| 4 |
NetEase
NTES
|
$202M |
| 5 |
Trip.com Group
TCOM
|
$95M |
Sector Composition
| 1 | Consumer Discretionary | 35.58% |
| 2 | Technology | 17.59% |
| 3 | Communication Services | 16.9% |
| 4 | Healthcare | 11.23% |
| 5 | Real Estate | 6.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Atara Biotherapeutics
ATRA
$90.7M
| $200K | 0.02% |
1,025
+248
| +32% | +$48.4K |
|
302
Kura Oncology
KURA
$713M
| $194K | 0.02% |
+10,573
| New | +$194K |
|
303
Anavex Life Sciences
AVXL
$807M
| $193K | 0.02% |
19,244
+777
| +4% | +$7.79K |
|
304
uniQure
QURE
$985M
| $193K | 0.02% |
+10,364
| New | +$193K |
|
305
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $188K | 0.02% |
25,990
+12,504
| +93% | +$90.4K |
|
306
FibroGen
FGEN
$48.9M
| $184K | 0.02% |
698
+142
| +26% | +$37.4K |
|
307
Hewlett Packard
HPE
$31B
| $181K | 0.02% |
13,665
-125
| -0.9% | -$1.66K |
|
308
MannKind Corp
MNKD
$1.7B
| $177K | 0.02% |
46,376
+2,887
| +7% | +$11K |
|
309
Alector
ALEC
$305M
| $166K | 0.02% |
16,372
+4,938
| +43% | +$50.1K |
|
|
MYOV
310
DELISTED
Myovant Sciences Ltd.
MYOV
| $150K | 0.01% |
12,091
-1,510
| -11% | -$18.7K |
|
311
Catalyst Pharmaceutical
CPRX
$2.48B
| $150K | 0.01% |
21,335
+9,721
| +84% | +$68.3K |
|
|
RDUS
312
DELISTED
Radius Health, Inc.
RDUS
| $142K | 0.01% |
13,662
+924
| +7% | +$9.6K |
|
313
Rigel Pharmaceuticals
RIGL
$742M
| $141K | 0.01% |
12,482
+10,735
| +614% | +$121K |
|
314
Gossamer Bio
GOSS
$668M
| $137K | 0.01% |
+16,419
| New | +$137K |
|
315
Sangamo Therapeutics
SGMO
$165M
| $131K | 0.01% |
31,592
+8,491
| +37% | +$35.2K |
|
316
Organogenesis Holdings
ORGO
$634M
| $126K | 0.01% |
25,808
+14,028
| +119% | +$68.5K |
|
317
Norwegian Cruise Line
NCLH
$11.6B
| $118K | 0.01% |
+10,598
| New | +$118K |
|
318
Viatris
VTRS
$12.2B
| $117K | 0.01% |
11,183
-1,905
| -15% | -$19.9K |
|
|
EQRX
319
DELISTED
EQRx, Inc. Common Stock
EQRX
| $103K | 0.01% |
+21,875
| New | +$103K |
|
320
Praxis Precision Medicines
PRAX
$986M
| $64K | 0.01% |
+1,738
| New | +$64K |
|
321
Geron
GERN
$893M
| $60K | 0.01% |
38,992
+7,305
| +23% | +$11.2K |
|
322
MiMedx Group
MDXG
$1.06B
| $42K | ﹤0.01% |
11,994
+1,321
| +12% | +$4.63K |
|
|
ADAG
323
Adagene
ADAG
$104M
| $39K | ﹤0.01% |
19,310
| – | – |
|
324
McKesson
MCK
$85.5B
| – | – |
-681
| Closed | -$208K |
|
325
Seres Therapeutics
MCRB
$169M
| – | – |
-744
| Closed | -$106K |
|